Lb Pharmaceuticals INC Form 4 insider transactions

Deep Track Biotechnology Master Fund, Ltd. and 2 others reported changes in beneficial ownership of Lb Pharmaceuticals Inc common stock on July 30, 2026.

Director Robert Ruffolo was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Ran Nussbaum was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Rebecca Luse was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Robert A. Lenz of LB Pharmaceuticals Inc. was granted 12,500 stock options as part of the company's director compensation policy.

Director Rekha Hemrajani was granted 10,000 stock options in LB Pharmaceuticals Inc. as part of a standard equity compensation arrangement.

Director William P. Kane Jr. was granted 10,000 stock options in LB Pharmaceuticals Inc. as part of a standard equity incentive.

Director J. Scott Garland was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

LB Pharmaceuticals' Chief Commercial Officer, Kaya Kamlesh Pai Panandiker, was granted 195,000 employee stock options with an exercise price of $21.36.

LB Pharmaceuticals' Senior Vice President of Finance, Marc L. Panoff, repriced a significant number of his employee stock options to the company's initial public offering price of $15 per share.

Deep Track Biotechnology Master Fund and affiliates significantly increased their beneficial ownership in LB Pharmaceuticals Inc. through a conversion of preferred stock and direct common stock purchases.

Pontifax Management 4 G.P. (2015) Ltd., a 10% owner and director, acquired 1,000,000 shares of LB PHARMACEUTICALS INC common stock at $15 per share, increasing its beneficial ownership to 1,411,681 shares.

LB Pharmaceuticals Director Ran Nussbaum, through Pontifax entities, significantly increased his indirect beneficial ownership in the company by acquiring 1,411,681 shares, including a $15 million purchase.

Vida Ventures entities and affiliates reported significant acquisitions of LB Pharmaceuticals common stock and conversions of preferred stock.

LB Pharmaceuticals Director Rekha Hemrajani was granted 22,449 stock options with a $15 exercise price, vesting over three years.

LB Pharmaceuticals Inc. Director Rebecca Luse was granted 22,449 stock options with an exercise price of $15, vesting over three years.

LB Pharmaceuticals Director William P. Kane Jr. was granted 22,449 stock options with an exercise price of $15, vesting over three years.

LB Pharmaceuticals Director Robert R. Ruffolo's stock options were repriced to $15 per share, aligning with the company's IPO price, and he received a new option award.

LB Pharmaceuticals Inc. repriced director Zachary Prensky's stock options to $15, matching the initial public offering price, effective September 10, 2025.

LB Pharmaceuticals Director Ran Nussbaum was granted 22,449 stock options with an exercise price of $15, vesting over three years.

LB Pharmaceuticals Director J. Scott Garland's stock options were repriced to the company's initial public offering price of $15 per share, effective September 10, 2025.

LB Pharmaceuticals' SVP of Technical Operations, Richard Silva, had stock options repriced to the company's initial public offering price of $15 per share.

LB Pharmaceuticals' Chief Medical Officer, Anna Eramo, had a significant portion of her stock options repriced to the company's initial public offering price of $15 per share.

LB Pharmaceuticals' Chief Business Officer, Gad Soffer, had existing stock options repriced to the company's IPO price of $15 per share, and received a new option grant.

LB Pharmaceuticals CEO Heather Turner's stock options were repriced to $15 per share, aligning with the company's initial public offering price.